Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes

Yang Liu; Jianying Liu; Jing Zou; Birte Kalveram; Rafael R.G. Machado; Ping Ren; Sina Türeli; Derek J. Smith; Scott C. Weaver; Xuping Xie; Pei-Yong Shi

doi:10.1038/s41392-022-01137-1

Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes

Yang Liu, Jianying Liu, Jing Zou, Birte Kalveram, Rafael R.G. Machado, Ping Ren, Sina Türeli, Derek J. Smith, Scott C. Weaver, Xuping Xie, Pei-Yong Shi

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Original language	English (US)
Article number	285
Journal	Signal Transduction and Targeted Therapy
Volume	7
Issue number	1
DOIs	https://doi.org/10.1038/s41392-022-01137-1
State	Published - Dec 2022

ASJC Scopus subject areas

Genetics
Cancer Research

Access to Document

10.1038/s41392-022-01137-1

Cite this

@article{521aebbaa7934dc2ad59c024af808d2f,

title = "Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes",

author = "Yang Liu and Jianying Liu and Jing Zou and Birte Kalveram and Machado, {Rafael R.G.} and Ping Ren and Sina T{\"u}reli and Smith, {Derek J.} and Weaver, {Scott C.} and Xuping Xie and Pei-Yong Shi",

note = "Funding Information: We thank Phillip R. Dormitzer for his helpful discussions during the study. We thank Sam Wilks, Barbara M{\"u}hlemann, and Eric LeGresley for discussions on Antigenic Cartography. P.-Y.S. was supported by NIH grants HHSN272201600013C, U01AI151801 and UL1TR001439, and awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Robert Foundation. S.C.W. was supported by NIH grant R24 AI120942. P.R. and X.X. were partially supported by the Sealy & Smith Foundation. J.L. was supported by James W. McLaughlin Fellowship Fund. S.T. and D.J.S. were supported by the NIH NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract 75N93021C00014 as part of the SAVE program. Funding Information: We thank Phillip R. Dormitzer for his helpful discussions during the study. We thank Sam Wilks, Barbara M{\"u}hlemann, and Eric LeGresley for discussions on Antigenic Cartography. P.-Y.S. was supported by NIH grants HHSN272201600013C, U01AI151801 and UL1TR001439, and awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Robert Foundation. S.C.W. was supported by NIH grant R24 AI120942. P.R. and X.X. were partially supported by the Sealy & Smith Foundation. J.L. was supported by James W. McLaughlin Fellowship Fund. S.T. and D.J.S. were supported by the NIH NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract 75N93021C00014 as part of the SAVE program. ",

year = "2022",

month = dec,

doi = "10.1038/s41392-022-01137-1",

language = "English (US)",

volume = "7",

journal = "Signal Transduction and Targeted Therapy",

issn = "2095-9907",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes

AU - Liu, Yang

AU - Liu, Jianying

AU - Zou, Jing

AU - Kalveram, Birte

AU - Machado, Rafael R.G.

AU - Ren, Ping

AU - Türeli, Sina

AU - Smith, Derek J.

AU - Weaver, Scott C.

AU - Xie, Xuping

AU - Shi, Pei-Yong

N1 - Funding Information: We thank Phillip R. Dormitzer for his helpful discussions during the study. We thank Sam Wilks, Barbara Mühlemann, and Eric LeGresley for discussions on Antigenic Cartography. P.-Y.S. was supported by NIH grants HHSN272201600013C, U01AI151801 and UL1TR001439, and awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Robert Foundation. S.C.W. was supported by NIH grant R24 AI120942. P.R. and X.X. were partially supported by the Sealy & Smith Foundation. J.L. was supported by James W. McLaughlin Fellowship Fund. S.T. and D.J.S. were supported by the NIH NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract 75N93021C00014 as part of the SAVE program. Funding Information: We thank Phillip R. Dormitzer for his helpful discussions during the study. We thank Sam Wilks, Barbara Mühlemann, and Eric LeGresley for discussions on Antigenic Cartography. P.-Y.S. was supported by NIH grants HHSN272201600013C, U01AI151801 and UL1TR001439, and awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Robert Foundation. S.C.W. was supported by NIH grant R24 AI120942. P.R. and X.X. were partially supported by the Sealy & Smith Foundation. J.L. was supported by James W. McLaughlin Fellowship Fund. S.T. and D.J.S. were supported by the NIH NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract 75N93021C00014 as part of the SAVE program.

PY - 2022/12

Y1 - 2022/12

UR - http://www.scopus.com/inward/record.url?scp=85135961431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135961431&partnerID=8YFLogxK

U2 - 10.1038/s41392-022-01137-1

DO - 10.1038/s41392-022-01137-1

M3 - Letter

C2 - 35963863

AN - SCOPUS:85135961431

SN - 2095-9907

VL - 7

JO - Signal Transduction and Targeted Therapy

JF - Signal Transduction and Targeted Therapy

IS - 1

M1 - 285

ER -

Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this